FDA science forum
This article was originally published in The Tan Sheet
Experts from FDA, industry and academia will discuss new challenges in food and drug regulation during FDA's Annual Science Forum in Washington, D.C. April 18-20. Presentations will address quantitative approaches to regulation and "a perspective on FDA science" in light of agency's Centennial, FDA notes. The forum will include plenary lectures on innovation and public health preparedness. Registration forms are available through FDA's website...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.